

Table 4. Relation of serum uric acid level to cardiovascular disease mortality.

	Uric Acid Level, mg/dl	No. of Deaths	Mortality Rate*	Age Adjusted		Fully Adjusted [†]	
				Hazard Ratio	95% CI	Hazard Ratio	95% CI
Cardiovascular disease mortality							
Men	< 5.0	266	10.3	1.0		1.0	
	5.0–5.9	201	7.7	0.89	0.74, 1.07	0.89	0.74, 1.07
	6.0–6.9	156	7.5	0.94	0.77, 1.14	0.83	0.67, 1.01
	7.0–7.9	65	7.0	0.94	0.71, 1.23	0.86	0.65, 1.13
	≥ 8.0	63	10.2	1.40	1.05, 1.83	1.08	0.81, 1.44
Women	< 4.0	457	5.6	1.0		1.0	
	4.0–4.9	382	6.5	1.06	0.92, 1.21	1.01	0.88, 1.15
	5.0–5.9	232	9.2	1.18	1.01, 1.38	1.08	0.91, 1.27
	6.0–6.9	111	14.9	1.91	1.54, 2.34	1.58	1.27, 1.96
	≥ 7.0	51	20.1	2.21	1.64, 2.93	1.79	1.31, 2.39
Coronary heart disease mortality							
Men	< 5.0	54	2.1	1.0		1.0	
	5.0–5.9	53	2.0	1.17	0.80, 1.71	1.14	0.78, 1.67
	6.0–6.9	33	1.6	0.99	0.63, 1.51	0.83	0.52, 1.28
	7.0–7.9	17	1.8	1.21	0.68, 2.04	1.02	0.56, 1.74
	≥ 8.0	20	3.2	2.14	1.25, 3.51	1.52	0.87, 2.58
Women	< 4.0	85	1.0	1.0		1.0	
	4.0–4.9	70	1.2	1.03	0.75, 1.42	0.96	0.69, 1.31
	5.0–5.9	49	1.9	1.33	0.93, 1.89	1.08	0.75, 1.55
	6.0–6.9	34	4.6	3.13	2.08, 4.62	2.28	1.47, 3.46
	≥ 7.0	12	4.7	2.67	1.38, 4.71	1.87	0.95, 3.38
Stroke mortality							
Men	< 5.0	139	5.4	1.0		1.0	
	5.0–5.9	96	3.7	0.83	0.64, 1.07	0.82	0.63, 1.07
	6.0–6.9	72	3.4	0.85	0.64, 1.13	0.76	0.56, 1.01
	7.0–7.9	30	3.2	0.85	0.56, 1.24	0.83	0.54, 1.22
	≥ 8.0	29	4.7	1.25	0.82, 1.84	0.95	0.61, 1.42
Women	< 4.0	216	2.7	1.0		1.0	
	4.0–4.9	175	3.0	1.01	0.83, 1.23	0.96	0.79, 1.18
	5.0–5.9	103	4.1	1.10	0.87, 1.39	1.01	0.79, 1.28
	6.0–6.9	48	6.4	1.71	1.23, 2.32	1.39	0.99, 1.91
	≥ 7.0	23	9.1	2.01	1.27, 3.03	1.67	1.05, 2.55

* Values are expressed per 1000 person-years. [†] In addition to age, adjusted for BMI, smoking status, alcohol consumption, systolic blood pressure, total cholesterol level, histories of hypertension, diabetes, coronary heart disease, kidney disease and malignant tumor, and estimated radiation dose from the atomic bombs.

subjects were divided into 3 groups depending on baseline age: < 45, 45–54, and ≥ 55 years. As shown in Table 5, in the age groups < 45 years (most subjects likely to be premenopausal) and ≥ 55 years (most subjects likely to be postmenopausal), a significant increase in hazard ratio for all-cause and cardiovascular mortality was observed with increasing uric acid levels. In the age group 45–54 years, which includes both menstrual and postmenopausal women, the association of uric acid level with mortality was not significant.

Since information about diuretic use was not available in our study, and since most users of diuretics are patients with hypertension, those individuals were excluded, and association of uric acid level with subsequent mortality was analyzed in women. As shown in Table 6, exclusion of hypertensive individuals (n = 1781) did not affect the association of uric acid level with all-cause and cardiovascular mortality

in women. Similarly, when the subjects were restricted to those without baseline cardiovascular disease, non-diabetics, non-smokers, and those with low total cholesterol (< 200 mg/dl), association of uric acid level with mortality did not substantially change except for cardiovascular mortality for those without baseline cardiovascular disease in the uric acid category ≥ 7.0 mg/dl (Table 6).

DISCUSSION

This large prospective study found that serum uric acid concentration is independently associated with cardiovascular mortality in women and with all-cause mortality in both men and women. Association of serum uric acid level with cardiovascular disease or mortality has been described in women in several other cohort studies^{2,6,7,11}, whereas the results in men are more inconsistent^{2-4,7-14}. Among 2 large prospective studies conducted recently in the United States,

Table 5. Relation of serum uric acid level to all-cause and cardiovascular mortality stratified by age among women (fully adjusted*).

Uric Acid Level, mg/dl	Baseline Age Category, yrs [†]					
	< 45		45–54		≥ 55	
	Hazard Ratio	95% CI	Hazard Ratio	95 % CI	Hazard Ratio	95% CI
All-cause mortality						
< 4.0	1.0		1.0		1.0	
4.0–4.9	1.15	0.92, 1.44	0.77	0.62, 0.95	1.13	1.02, 1.26
5.0–5.9	1.27	0.93, 1.70	0.96	0.74, 1.24	1.04	0.92, 1.19
6.0–6.9	2.11	1.32, 3.22	1.01	0.68, 1.47	1.45	1.21, 1.73
≥ 7.0	2.32	0.90, 4.86	1.28	0.67, 2.20	1.72	1.35, 2.16
Cardiovascular disease mortality						
< 4.0	1.0		1.0		1.0	
4.0–4.9	1.26	0.76, 2.07	0.78	0.54, 1.11	1.00	0.86, 1.17
5.0–5.9	1.55	0.80, 2.85	1.09	0.72, 1.63	1.00	0.82, 1.20
6.0–6.9	2.14	0.72, 5.11	1.23	0.66, 2.16	1.57	1.22, 1.99
≥ 7.0	5.88	1.36, 17.5	1.83	0.63, 4.27	1.74	1.23, 2.39

* In addition to age, adjusted for BMI, smoking status, alcohol consumption, systolic blood pressure, total cholesterol level, histories of hypertension, diabetes, coronary heart disease, kidney disease and malignant tumor, and estimated radiation dose from the atomic bombs. [†] The number of deaths due to all causes was 414, 509, and 2036 for the age categories < 45, 45–54, and ≥ 55 years, respectively. The number of deaths due to cardiovascular disease was 88, 193, and 952 for the same age categories, respectively.

Table 6. Relation of serum uric acid level to all-cause and cardiovascular mortality in women stratified by cardiovascular risk profiles (fully adjusted*).

Uric Acid Level, mg/dl	All-Cause		Cardiovascular	
	Hazard Ratio [†]	95% CI	Hazard Ratio	95 % CI
Non-hypertensives				
6.0–6.9	1.68	1.33, 2.09	1.88	1.25, 2.72
≥ 7.0	1.67	1.12, 2.38	1.99	1.00, 3.55
No cardiovascular disease				
6.0–6.9	1.42	1.21, 1.66	1.76	1.13, 2.63
≥ 7.0	1.62	1.28, 2.02	1.95	0.86, 3.81
Non-diabetics				
6.0–6.9	1.43	1.21, 1.67	1.52	1.19, 1.91
≥ 7.0	1.64	1.30, 2.06	1.79	1.28, 2.45
Non-smokers				
6.0–6.9	1.51	1.27, 1.78	1.71	1.32, 2.17
≥ 7.0	1.81	1.41, 2.29	2.02	1.41, 2.82
Low total cholesterol (< 200 mg/dl)				
6.0–6.9	1.51	1.18, 1.89	1.72	1.21, 2.40
≥ 7.0	1.80	1.28, 2.45	1.96	1.17, 3.11

* In addition to age, adjusted for BMI, smoking status, alcohol consumption, systolic blood pressure, total cholesterol level, histories of hypertension, diabetes, coronary heart disease, stroke, kidney disease and malignant tumor, and estimated radiation dose from the atomic bombs. [†] Hazard ratio for only 2 categories with high uric acid levels is presented.

the Framingham Heart Study showed no significant association of uric acid level with cardiovascular or all-cause mortality in either men or women⁹. The First National Health and Nutrition Examination Survey (NHANES I), on the other hand, showed a significant and independent association of uric acid level with cardiovascular and all-cause mortality in both sexes¹¹. Since both studies are population-based and their adjusted confounders are similar, the source for the difference in the results is unclear. Our study utilized

the largest cohort with the longest followup period among the cohorts so far analyzed, and adds further evidence for the association of uric acid level with cardiovascular mortality in women. Our population consisted entirely of Japanese subjects, and as shown in the baseline characteristics (Table 1), they are generally slimmer and have lower cholesterol levels compared with people in Western countries. Although such baseline factors were all adjusted in the analysis, ethnic differences existing in the study population might also have

played a role in the differences in results between our study and previous studies.

The strengths of our study are its large population size, long followup period, complete coverage of mortality during the followup period, and large number of subjects reaching the endpoint. Limitations include unavailability of information regarding diuretic use. Culleton, *et al* concluded that diuretic use was the major confounding factor in the apparent association of uric acid level with cardiovascular events among women in the Framingham Heart Study population⁹. On the other hand, several other studies including the NHANES I study have shown that the association of uric acid level with cardiovascular events or mortality remained significant even after adjustment for diuretic use^{5,11,15-18}. We performed an analysis excluding hypertensive individuals, the major users of diuretics, and obtained nearly identical results. Therefore, it seems unlikely that diuretic use was the source for the association of uric acid level with cardiovascular mortality in our study. Unavailability of information on serum creatinine level is one more limitation of our study. It has also been reported in other studies, however, that adjustment for serum creatinine level did not render the association of serum uric acid level with cardiovascular or total mortality insignificant^{5,11,15,16}. Other limitations may include misclassification of causes of death due to inaccuracy of diagnoses coded on death certificates.

Insulin resistance may be a plausible explanation for the association of uric acid level with cardiovascular disease risk since insulin resistance has been reported to be associated with both increased risk for cardiovascular events and increased serum uric acid levels^{22,23}. Several other mechanisms have also been suggested, including activation of platelets and cytokine production²⁴⁻²⁶. Oxygen free radicals are generated when xanthine oxidase produces uric acid, and this xanthine oxidase activity in vascular endothelial cells may be associated with impaired endothelial cell function, which may in turn lead to the development of atherosclerosis²⁷⁻²⁹. It has also been suggested that elevated serum uric acid level may be a compensatory mechanism to counteract oxidative damage related to atherosclerosis^{30,31}. In animal models, direct association of increased uric acid level with hypertension and uric acid-induced proliferation of vascular smooth muscle cells have been suggested^{32,33}.

The source for the difference in association of uric acid level with cardiovascular mortality between men and women in our study is unclear. A stronger association of uric acid level with cardiovascular disease in women than in men has also been reported in previous studies^{2,7}. In men, serum uric acid level is generally higher than in women, a phenomenon also observed in our study. The sex difference in serum uric acid level is largely due to the difference in renal clearance rate of uric acid: men have a lower clearance rate than women³⁴. Such physiological differences controlling serum uric acid level may be functioning in men in a way

that obscures the association of serum uric acid level with cardiovascular risk. It may not be the case that female hormones alone contributed to the closer association of uric acid level with mortality risk in women, because the analysis stratified by age in our study suggested that the association is significant in both premenopausal and postmenopausal women.

Our study showed that serum uric acid concentration is associated with cardiovascular mortality risk in women. Although the causal mechanism for such an association remains unknown, it can be inferred that serum uric acid level may be used in both clinical and healthcare settings as a marker reflecting cardiovascular disease risk especially for women.

REFERENCES

1. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. *Ann Intern Med* 1951;34:1421-31.
2. Reunanen A, Takkinen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. *Acta Med Scand* 1982;668 Suppl:49-59.
3. Yano K, Reed DM, McGee DL. Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to biologic and lifestyle characteristics. *Am J Epidemiol* 1984;119:653-66.
4. Brand FN, McGee DL, Kannel WB, Stokes J 3rd, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. *Am J Epidemiol* 1985;121:11-8.
5. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. *Acta Med Scand* 1988;224:549-55.
6. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. *J Clin Epidemiol* 1989;42:257-67.
7. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. *Am J Epidemiol* 1995;141:637-44.
8. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. *Heart* 1997;78:147-53.
9. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. *Ann Intern Med* 1999;131:7-13.
10. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. *World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology* 1999;10:391-7.
11. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971-1992. *JAMA* 2000;283:2404-10.
12. Moriarty JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. *Ann Epidemiol* 2000;10:136-43.
13. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male

- workers. *J Epidemiol* 2000;10:403-9.
14. Sakata K, Hashimoto T, Ueshima H, Okayama A. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. *Eur J Epidemiol* 2001;17:461-8.
 15. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. *Hypertension* 1999;34:144-50.
 16. Verdecchia P, Schillaci G, Reboldi G, Santeusano F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. *Hypertension* 2000;36:1072-8.
 17. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). *J Hypertens* 2000;18:1149-54.
 18. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. *Am J Cardiol* 2002;89:12-7.
 19. Lehto S, Niskanen L, Ronnema T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. *Stroke* 1998;29:635-9.
 20. Hollingsworth JW. Delayed radiation effects in survivors of the atomic bombings; review of the findings of the Atomic Bomb Casualty Commission, 1947-1959. *New Engl J Med* 1960;263:481-7.
 21. Atomic Bomb Casualty Commission. Research plan for joint ABCC-JNIH Adult Health Study in Hiroshima and Nagasaki. ABCC Technical Report, Hiroshima, 1962;11-62.
 22. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. *Circulation* 1996;93:1809-17.
 23. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. *JAMA* 1991;266:3008-11.
 24. Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. *J Clin Invest* 1977;60:999-1007.
 25. Roberge CJ, de Medicis R, Dayer JM, Rola-Pleszczynski M, Naccache PH, Poubelle PE. Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. *J Immunol* 1994;152:5485-94.
 26. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. *Blood* 1997;89:577-82.
 27. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. *Hypertension* 1997;30:57-63.
 28. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. *Hypertension* 2000;35:746-51.
 29. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. *Circulation* 2002;105:2619-24.
 30. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? *Atherosclerosis* 2000;148:131-9.
 31. Kirschbaum B. Renal regulation of plasma total antioxidant capacity. *Med Hypotheses* 2001;56:625-9.
 32. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension* 2001;38:1101-6.
 33. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. *Hypertension* 2003;41:1287-93.
 34. Adamopoulos D, Vlassopoulos C, Seitanides B, Contoyiannis P, Vassilopoulos P. The relationship of sex steroids to uric acid levels in plasma and urine. *Acta Endocrinol* 1977;85:198-208.

Smoking and fracture risk: a meta-analysis

J. A. Kanis · O. Johnell · A. Oden · H. Johansson
C. De Laet · J. A. Eisman · S. Fujiwara · H. Kroger
E. V. McCloskey · D. Mellstrom · L. J. Melton · H. Pols
J. Reeve · A. Silman · A. Tenenhouse

Received: 14 January 2004 / Accepted: 19 March 2004 / Published online: 3 June 2004
© International Osteoporosis Foundation and National Osteoporosis Foundation 2004

Abstract Smoking is widely considered a risk factor for future fracture. The aim of this study was to quantify this risk on an international basis and to explore the relationship of this risk with age, sex and bone mineral density (BMD). We studied 59,232 men and women (74% female) from ten prospective cohorts comprising EVOS/EPOS, DOES, CaMos, Rochester, Sheffield, Rotterdam, Kuopio, Hiroshima and two cohorts from Gothenburg. Cohorts were followed for a total of 250,000 person-years. The effect of current or past smoking, on the risk of any fracture, any osteoporotic fracture and hip fracture alone was examined using a Poisson model for each sex from each cohort. Covariates examined were age, sex and BMD. The results of the different studies were merged using the weighted β -coefficients. Current smoking was associated with a significantly increased risk of any fracture compared to

non-smokers (RR=1.25; 95% Confidence Interval (CI)=1.15–1.36). Risk ratio (RR) was adjusted marginally downward when account was taken of BMD, but it remained significantly increased (RR=1.13). For an osteoporotic fracture, the risk was marginally higher (RR=1.29; 95% CI=1.13–1.28). The highest risk was observed for hip fracture (RR=1.84; 95% CI=1.52–2.22), but this was also somewhat lower after adjustment for BMD (RR=1.60; 95% CI=1.27–2.02). Risk ratios were significantly higher in men than in women for all fractures and for osteoporotic fractures, but not for hip fracture. Low BMD accounted for only 23% of the smoking-related risk of hip fracture. Adjustment for body mass index had a small downward effect on risk for all fracture outcomes. For osteoporotic fracture, the risk ratio increased with age, but decreased with age for hip fracture. A smoking history was associated with a sig-

J. A. Kanis (✉) · E. V. McCloskey
WHO Collaborating Centre for Metabolic Bone Diseases,
University of Sheffield Medical School, Beech Hill Road,
Sheffield, S10 2RX, UK
E-mail: w.j.pontefract@shef.ac.uk
Tel: +44-114-2851109
Fax: +44-114-2851813

O. Johnell
Department of Orthopaedics, Malmö General Hospital,
Malmö, Sweden

A. Oden
Gothenburg, Sweden

H. Johansson
Gothenburg, Sweden

C. De Laet
Department of Public Health, Erasmus Medical Center,
Rotterdam, The Netherlands

J. A. Eisman
Garvan Institute of Medical Research,
St Vincent's Hospital, NSW, Australia

S. Fujiwara
Department Clinical Studies,
Radiation Effects Research Foundation,
Hiroshima, Japan

H. Kroger
Department of Surgery, Kuopio University Hospital,
Kuopio, Finland

D. Mellstrom
Department Geriatric Medicine, University of Goteborg,
Goteborg, Sweden

L. J. Melton
Division of Epidemiology, Mayo Clinic,
Rochester, MN, USA

H. Pols
Department of Internal Medicine,
Erasmus University,
Rotterdam, The Netherlands

J. Reeve
Strangeways Research Laboratories,
Cambridge, UK

A. Silman
ARC Epidemiology Research Unit,
University of Manchester,
Manchester, UK

A. Tenenhouse
Division of Bone Metabolism,
The Montreal General Hospital,
Montreal, Canada

nificantly increased risk of fracture compared with individuals with no smoking history, but the risk ratios were lower than for current smoking. We conclude that a history of smoking results in fracture risk that is substantially greater than that explained by measurement of BMD. Its validation on an international basis permits the use of this risk factor in case finding strategies.

Keywords Body mass index · Hip fracture · Meta-analysis · Osteoporotic fracture · Smoking

Introduction

It is well established that smoking is associated with a reduction in bone mineral density (BMD) in postmenopausal women and men [1]. A meta-analysis has suggested that the risk of hip fracture may also be markedly increased [2]. In current smokers, the risk of hip fracture compared with non-smokers was similar in women up to the age of 50 years. However, it increased thereafter, to a risk ratio (RR) of 1.17 at 60 years, 1.41 at 70 years and 1.71 at 80 years. In 90-year-old women the risk ratio was 2.08 [2]. In population-based samples, the risk of other osteoporotic fractures also appears to increase [3], but this is not an invariant finding [4]. The risk of forearm fractures does not appear to increase among smokers [3, 5, 6].

Increased fracture risk may in part be due to the fact that patients who smoke have low BMD [1]. Studies adjusted for BMD suggest that the relative risk is only modestly adjusted downward [7]. In the meta-analysis of Law and Hackshaw [2], although the difference in bone density between smokers and non-smokers was not apparent at age 50, it became noticeable with increasing age, so that at age 80 bone mineral density at the hip was 0.45 SD lower in smokers, as compared with non-smokers. From the relationship between bone mineral density in the hip and hip-fracture risk, the risk ratio in smokers was estimated at 1.56, compared with a direct

estimate of 1.71 for hip fractures. This led the authors to suppose that the majority of any risk was attributable to decreased bone density.

The association between smoking and subsequent fracture risk has led to the inclusion of current smoking as a risk factor in assessment guidelines in the United States and Canada [8, 9], if not in Europe [11, 12, 13]. Since smoking is considered a risk factor, partly independent of BMD, intervention is recommended in smokers with a *T*-score for BMD of -1.5 , whereas in non-smokers the intervention threshold is set at -2.0 SD. Attention has focused recently on assessing fracture probability by using multiple risk factors, rather than BMD alone, to provide intervention thresholds [8, 14, 15]. This demands knowledge of the interrelationships between these risk factors. The aim of our study was to quantify, in an international setting, the risk associated with smoking for future fractures and to explore the dependence of this risk on age, sex, body mass index (BMI) and BMD.

Materials and methods

We studied 59,232 men and women, of whom 18% had a history of current smoking, taken from ten prospectively studied cohorts. Brief details of these cohorts appear below and are summarized in Table 1.

CaMos

The Canadian Multicentre Osteoporosis Study (CaMos) is a current, prospective age-stratified cohort. The study documents the incidence of fractures and risk factors in a random sample of 9,424 men and women aged 25 years or older, selected by telephone listings. The sampling frame is from nine study centers in seven provinces [16]. Individuals were characterized by interview. BMD was measured by DXA (Dual X-ray absorptiometry) at the hip, using the Hologic QDR in seven centers and the Lunar DPX Alpha in two centers.

Table 1 Details of cohorts studied

Cohort	Sample size	% Women	Person-years	Mean age (years)	Smoking history (%)		Any kind of fracture	Osteoporotic fracture	Hip fracture
					Current	Ever			
CaMos	9,401	69	26,656	62.1	-	54	586	316	42
DOES	2,163	61	16,333	70.7	8	41	532	418	107
EVOS/EPOS	13,841	52	41,429	63.8	20	52	731	731	50
Gothenburg I	2,320	61	16,255	78.7	15	41	424	424	332
Gothenburg II	7,012	100	29,335	58.9	25	49	433	438	29
Hiroshima	1,937	69	7,563	64.8	20	34	134	64	21
Kuopio	11,798	100	56,602	52.3	11	-	1,053	-	-
Rochester	998	65	6,212	56.8	-	47	289	244	42
Rotterdam	7,590	60	42,613	70.1	23	63	967	746	271
Sheffield	2,172	100	6,900	80.0	7	46	290	241	63
Totals	59,232	74	249,898	62.8	18	52	5,444	3,495	957

DOES

The Dubbo Osteoporosis Epidemiology Study (DOES) is a population-based study with multiple assessments of skeletal status in men and women from Dubbo, Australia, and at least 60 years old [17, 18]. Study participation was 56% of the population. Baseline measurements included BMD at the femoral neck, assessed using DXA (GE-Lunar, DPX and Prodigy). Fractures are identified through radiologists' reports from the two centers servicing the region.

EVOS/EPOS

The European Vertebral Osteoporosis Study (EVOS) comprised age- and sex-stratified random samples from 36 centers in 19 European countries [19]. Equal numbers of men and women were drawn in each center within six sequential 5-year age bands (from 50 to 79 years). A baseline radiograph for vertebral-fracture prevalence was undertaken in 15,570 men and women. BMD was measured in 3,461 men and women from 13 centers, by DXA at the femoral neck using pencil-beam machines cross-calibrated with the European spine phantom. The sample provided the framework for the European Prospective Osteoporosis study (EPOS), in which repeated assessment was undertaken in 29 of the centers [20, 21].

Gothenburg I

This study comprised four birth cohorts of 2,375 randomly sampled men and women aged at least 70, followed for up to 20 years in Gothenburg, [22, 23] after a baseline BMD measurement. Participants were drawn randomly from the Gothenburg population register by date of birth, to provide cohorts aged 70, 76, 79 and 85 years at the time of investigation. Bone mineral density was measured at the right heel using dual photon absorptiometry.

Gothenburg II

The Gothenburg study comprised a randomly drawn population cohort of approximately 7,000 women aged 21–89, followed for up to 7.9 years (mean = 4.2 years) [24]. Seventy percent of those invited participated in the study, which examined risk factors for osteoporosis through a standardized questionnaire. BMD was assessed at baseline at the distal forearm, using the Osteometer DTX 200.

Hiroshima

The Adult Health Study in Hiroshima (AHS) was established to document late health effects of radiation

exposure among atomic-bomb survivors in Hiroshima and Nagasaki. The original AHS cohort consisted of about 15,000 atomic-bomb survivors and 5,000 controls selected from residents in Hiroshima and Nagasaki, using the 1950 national census supplementary schedules and the Atomic Bomb Survivors Survey. AHS subjects have been followed through biennial medical examinations since 1958, with a participation rate of approximately 80%. BMD at the lumbar spine and proximal femur has been measured at each biennial health examination using DXA (Hologic QDR-2000) since December 1993. At each examination, trained nurses interviewed subjects about fractures and measured height and weight [25, 26].

Kuopio

The Kuopio Osteoporosis Risk Factor and Prevention (OSTPRE) study in Finland was based on a postal enquiry sent to all of the 14,220 women aged 47–56 residing in Kuopio province in 1989. Of these, 13,100 responded, 1,214 of whom were excluded due to incomplete information. This left a study population of 11,886 women. A random stratified sample of 3,222 underwent bone mineral densitometry at the femoral neck, with DXA using the Lunar DPX [27].

Rochester

The Rochester cohort was recruited from two random population samples stratified by decade of age. One sample included women who were followed for up to 20 years [28], and the other was composed of women and men followed for 8 years [29]. BMD of the right femoral neck was measured—by dual photon absorptiometry for the first cohort (cross-calibrated to DXA), and by DXA (Hologic QDR 2000) for the second group. Fractures were ascertained by periodic interview combined with review of the inpatient and outpatient medical records of all local care providers.

Rotterdam

The Rotterdam study, begun in 1990, was a prospective cohort study that aimed to examine and follow up on all residents aged 55 years and older living in Ommoord, a district of Rotterdam [30]. By 1993, 7,983 residents had been included (response rate 78%). Bone mineral density was assessed at the femoral neck by DXA, using a Lunar DPX-L. Fracture follow-up was done using an automated link with general practitioner computer systems and hospital admission data [31]. Fracture data were collected and validated by two independent research physicians. For this analysis, validated fracture follow-up was available for 7,590 participants (3,012 men), with an average follow-up time of 6 years.

Sheffield

The Sheffield cohort comprised women aged 75 years or older, selected randomly from the population of Sheffield, UK, and surrounding districts, between 1993 and 1999. Approximately 35,000 women, identified from general practitioner listings, were contacted by letter and invited for assessment of their skeletal status. Of the 5,873 women agreeing to attend the screening visit, 281 were excluded. The remainder were randomly allocated after they gave informed consent to treatment with the bisphosphonate clodronate, or to an identical placebo. This study is still in progress. The material used for the present paper included 2,148 women allocated to treatment with placebo [32]. All women had baseline assessment of BMD at the femoral neck, using the Hologic 4500. Outcomes were assessed by home visits at 6-month intervals.

Baseline and outcome variables

A history of current or past smoking was obtained by self-report. For the EVOS/EPOS, Hiroshima and Gothenburg I cohorts, this was recorded as past or current use of tobacco. For the Gothenburg II cohort, the same data were collected, but use for 6 months qualified as past or current use. For Rotterdam, Sheffield and DOES, tobacco use was recorded as previous, current or never. Data on current smoking was not available for two cohorts (CaMos and Rochester). Height and weight were measured using standard techniques in all cohorts. BMI was calculated as weight in kg divided by height squared in m. Bone mineral density was assessed by multiple techniques as described above. For the purposes of this analysis, we utilized BMD assessed at the femoral neck by DXA, with the exception of the Gothenburg cohorts, for which BMD was assessed by DPA at the heel and DXA at the distal forearm.

Fractures were ascertained from self-reports (Sheffield, Kuopio, EVOS/EPOS, Hiroshima) and/or verified from hospital or central databases (Gothenburg, CaMos, DOES, Sheffield, EVOS/EPOS, Rochester, Rotterdam). The EPOS study also included sequential systematic radiography to define incident vertebral deformities, but the data were not used in this analysis. Our analysis used information on any kind of clinical fracture and on clinical fractures considered to be osteoporotic. In addition, hip fracture was considered separately. An osteoporotic fracture was one that the investigator considered to be due to osteoporosis, except as indicated below. For the EVOS/EPOS study, osteoporotic fractures comprised hip, forearm, humeral or spine fractures. For the CaMos study, they comprised fractures of the spine, pelvis, ribs, distal forearm, forearm and hip. In the other cohorts (Sheffield, Rotterdam, Rochester, Gothenburg I and II, Hiroshima) fractures at sites considered characteristic for osteoporosis were

extracted [33]. Details about the number of participants, gender and fractures are provided in Table 1.

Statistical methods

The risk of fracture was estimated by Poisson regression, applied separately to each cohort and sex [32]. Covariates included time since start of follow-up, current age, history of smoking, and BMD. We also excluded BMD from the model. The beta coefficient for each sex in each cohort is age-dependent, $\beta_{k+1} + \beta_{k+1} \times \text{age}$. The estimated value of the β coefficients and their variance was determined for each age within the range of 50 to 85 years. Results of each cohort and both sexes were weighted according to the variance and merged to determine the weighted mean and standard deviations. The risk ratio of those who currently smoked or ever smoked versus those without a smoking history was equal to weighted e^{mean} . In further models, we examined the effects including BMI with and without BMD. There was little heterogeneity between cohorts in the relationship between hip-fracture risk and smoking ($I^2 = 12\%$; 95% CI (confidence interval) = 0–53%), and a fixed-effect model was used [34].

The component of the risk ratio explained by BMD was computed from a meta-analysis of BMD and fracture risk [35]. The risk of any fracture was assumed to increase 1.6-fold for each SD decrease in BMD. For hip fracture, the gradient of risk was assumed to be 2.6 per SD. The proportion of risk attributed to a low BMD was computed as

$$\frac{[\log \text{RR}_a / \log \text{GR}] - [\log \text{RR}_b / \log \text{GR}]}{[\log \text{RR}_a / \log \text{GR}]}$$

Where RR_a is the unadjusted risk ratio, RR_b is the risk ratio adjusted for BMD, and GR is the gradient of risk.

Results

Of 59,232 men and women studied, 867 men and 4,577 women were identified as having a subsequent fracture

Table 2 Prevalence of smoking history in men and women by age

Age (years)	Probability of smoking (%)		
	Men	Women	Combined
50	41.3	26.8	32.9
55	37.2	22.3	28.4
60	33.3	18.3	24.3
65	29.6	15.0	20.6
70	26.1	12.1	17.4
75	22.9	9.7	14.6
80	20.0	7.8	12.1
85	17.4	6.2	10.0

(any kind), of which 677 men and 2,817 women were characterized as osteoporotic. Of these, 207 men and 750 women sustained a hip fracture. The total follow-up in person years was 61,563 in men and 188,334 in women. BMD measurements were available in 36,550 individuals (64%) and BMI in 96%. The prevalence of smoking among the cohorts decreased almost linearly with age in men and women ($p < 0.001$; Table 2). At all ages, current smoking was higher in men than in women.

Current smoking

Current smoking was associated with a significantly increased risk of any kind of fracture, including osteoporotic or hip fractures taken alone, in both men and women (Table 3). For any kind of fracture and for osteoporotic fractures taken alone, the risk in smokers was significantly higher in men ($p = 0.015$) than in women ($p = 0.03$). For hip fractures taken alone, there was no difference in the risk ratio between men and women. For men and women combined, risk with current smoking was highest for hip fracture ($RR = 1.84$), lowest for fractures taken overall ($RR = 1.25$) and intermediate for osteoporotic fracture ($RR = 1.29$).

Risk ratio was adjusted downward somewhat when taking BMD into account (see Table 3). In women, for any fracture overall or osteoporotic fracture specifically, the associations between smoking and fracture were no longer significant. In men, the effect was less marked or not apparent. In men and women together, low BMD accounted for the minority of the risk associated with current smoking. For fractures overall, 45% of the risk was explained by BMD, whereas for osteoporotic fracture alone it was 40% and for hip fracture, only 23%.

BMI

The risk ratios for smokers were also adjusted downward when account was taken for BMI, though all ratios remained significantly increased (Table 4). The downward adjustment was less than the adjustment for BMD alone. When smoking, BMI and BMD were entered into the model, a further decrease in risk ratio was observed, although the risk ratios remained above unity, significantly so for the risk of (any) fractures overall and for hip fracture.

Table 5 Risk ratio (*RR*) and 95% confidence intervals (*CI*) for osteoporotic and hip fractures in current smokers for men and women combined

Age (years)	Without BMD		Adjusted for BMD	
	<i>RR</i>	95% <i>CI</i>	<i>RR</i>	95% <i>CI</i>
(a) Osteoporotic fracture				
50	1.05	0.80–1.37	0.82	0.57–1.18
55	1.06	0.86–1.30	0.85	0.65–1.12
60	1.08	0.92–1.26	0.88	0.72–1.08
65	1.14	1.00–1.30	0.91	0.76–1.09
70	1.27	1.12–1.45	1.01	0.85–1.20
75	1.45	1.28–1.65	1.20	1.01–1.43
80	1.54	1.34–1.77	1.30	1.08–1.57
85	1.52	1.28–1.80	1.28	1.00–1.63
(b) Hip fracture				
50	2.52	1.24–5.10	2.28	0.94–5.51
55	2.35	1.32–4.19	2.09	1.03–4.24
60	2.17	1.38–3.44	1.87	1.07–3.25
65	1.98	1.38–2.86	1.68	1.07–2.65
70	1.92	1.42–2.60	1.69	1.15–2.48
75	1.94	1.52–2.49	1.76	1.30–2.37
80	1.91	1.55–2.35	1.69	1.31–2.19
85	1.80	1.43–2.26	1.57	1.16–2.13

Table 3 Risk ratio of fracture (*RR*) and 95% confidence interval (*CI*) associated with current smoking by fracture outcome in men and women

Outcome	Sex	<i>RR</i>	95% <i>CI</i>	<i>RR</i> ^a	95% <i>CI</i>
Any kind of fracture	M	1.50	1.26–1.77	1.49	1.20–1.84
	F	1.18	1.07–1.30	1.02	0.90–1.16
	M + F	1.25	1.15–1.36	1.13	1.01–1.25
Osteoporotic Fracture	M	1.53	1.27–1.83	1.54	1.21–1.95
	F	1.20	1.06–1.35	1.01	0.87–1.17
	M + F	1.29	1.17–1.43	1.13	1.00–1.28
Hip fracture	M	1.82	1.34–2.49	1.69	1.16–2.48
	F	1.85	1.46–2.34	1.55	1.16–2.07
	M + F	1.84	1.52–2.22	1.60	1.27–2.02

^aRisk ratio adjusted for BMD

Table 4 Risk ratio (*RR*) for fracture in current smokers (men and women combined) adjusted for age, BMD, BMI and both BMD and BMI. *CI* confidence interval

Adjustment	Outcome fracture					
	Any		Osteoporotic		Hip	
	<i>RR</i>	95% <i>CI</i>	<i>RR</i>	95% <i>CI</i>	<i>RR</i>	95% <i>CI</i>
Age	1.25	1.15–1.36	1.29	1.17–1.43	1.84	1.52–2.22
Age BMD	1.13	1.01–1.25	1.13	1.00–1.28	1.60	1.27–2.02
Age BMI	1.19	1.09–1.30	1.21	1.08–1.34	1.65	1.34–2.03
Age, BMI, BMD	1.12	1.01–1.25	1.11	0.98–1.26	1.55	1.23–1.96

Age

Risk ratios increased with age for any fracture and for osteoporotic fractures specifically, but they were significantly higher than unity at all ages (Table 5). With adjustment for BMD, current smoking was a significant risk only from the age of 70 years. In contrast, for hip fracture risk, the risk ratio decreased with age but was significantly higher than unity at all ages with or without adjustment for BMD.

Ever-smokers

A history of smoking (ever smoked) was also associated with a significant risk increase for any fracture, and, specifically, for an osteoporotic or hip fracture (Table 6). The risk ratios were lower than for current smoking (see Table 3), but, just as in that case, were highest for hip fracture. There was no significant difference in risk ratio between men and women, no difference when adjusted for BMD, and no significant effect of age on the risk ratio (data not shown). The exclusion of data from the Gothenburg cohorts (where BMD was assessed at the heel or forearm) had no material effect on these results (data not shown).

Discussion

The present study confirms that a history of smoking carries a modest but significant risk for future fractures. In addition, the effect of smoking is over and above that which can be explained by variations in BMD. The risk of subsequent fractures was greater in the case of hip fracture than for all fractures, and intermediate for osteoporotic fractures. For hip-fracture risk in women, the increase in risk ratio (1.85) was comparable to that described in the meta-analysis from Law and Hackshaw [2]. In their findings, risk ratios increased with age; however, in the present study risk ratios for hip fracture tended to decrease with age. In contrast, risk ratios for osteoporotic fractures (which included hip fractures)

Table 6 Risk ratio (*RR*) associated with a smoking history by subsequent fracture outcome in men and in women. *RR* is not adjusted for BMD

Outcome	Sex	<i>RR</i>	95% confidence interval
Any fracture	M	1.27	1.07–1.51
	F	1.18	1.10–1.26
	M + F	1.19	1.12–1.27
Osteoporotic fracture	M	1.34	1.10–1.63
	F	1.15	1.07–1.25
	M + F	1.18	1.09–1.27
Hip fracture	M	1.11	0.67–1.83
	F	1.42	1.18–1.72
	M + F	1.38	1.15–1.65

increased with age. The strength of the association we found was lower than for ever-smokers, consistent with the view that the effect of smoking appears to wane slowly after a person stops smoking [36].

A particular strength of the present study is that the estimate of risk is from an international setting, from randomly or quasi-randomly selected population cohorts, and the calculations were based on the primary data. This decreases the risk of publication and selection biases, which may have large effects. For example, in the large, prospective study from Kuopio, the risk of fracture for current smokers was 1.47 (95% CI = 1.05–2.06) when the sample included individuals selected on the basis of risk factors. From the random population sample used in the present study, the relative risk for fractures overall was 1.18 (95% CI = 0.70–2.00) [3]. Furthermore, the consistency of the association within cohorts indicates the generalizability of this risk factor's importance.

The large sample size studied permitted us to examine risk by age. For all fractures and for osteoporotic fractures specifically, the risk ratios were relatively constant with age. If anything, they tended to increase with age. In the case of hip fracture, risk ratios decreased with age, but this was not significant. Much larger samples would be needed to verify such an effect. A limitation of this study was that we were unable to examine the dose dependency of the association, due to differences in the way that smoking histories were obtained. In this regard, men tend to smoke more than women. This may account for the slightly higher risk ratios observed in men.

The present study also quantifies the independent contributions of low BMD or BMI to the risks associated with smoking. Low BMD explained a minority of the total risk, contradicting the findings of Law and Hackshaw [2] but agreeing with others [7]. With regard to BMD, there are several mechanisms whereby smoking might adversely affect fracture risk. Female smokers may have increased rates of bone loss after menopause [37], but this is not consistently found [38, 39]. Smoking women also have earlier menopause [37, 40, 41]. It has been suggested that smoking may enhance estrogen catabolism [42]. The effects of hormone replacement therapy (HRT) have in some, but not all, studies been attenuated among smokers [43, 44]. Smokers are also thinner and, hence, have lower body mass index [40, 45]. Consequently, the protective effect of adipose tissue and peripheral estrogen metabolism is impaired. Bone loss is reported to be higher in male smokers than in female smokers [38], perhaps due to men's higher exposure to cigarette smoking. We observed higher risk ratios for men than for women for any fracture and for osteoporotic fracture specifically. Such effects may explain the component of fracture risk that is attributable to low BMD or BMI. However, as shown in the present study, this represents a minority of the risk.

The mechanism for the BMD-independent increase in risk could not be determined from this study. Possibly, it results, in part, from lower levels of physical activity or

to co-existing morbidity, which might in turn increase the risk of falls or impair protective responses to injury [46, 47, 48]. It is also possible that smoking-induced changes in the microarchitecture of cancellous bone would weaken the resistance to mechanical force out of proportion to any effect on BMD. Finally, errors in measurement of BMD [49] will result in the underestimation of bone's contribution to fracture risk.

Whatever the mechanism involved, these data indicate that the risk of fractures is greater for smokers and those with a history of smoking than it is for individuals of the same age, sex and BMD who do not or did not smoke. This has implications for intervention thresholds. Health economic analyses suggest that intervention is cost-effective when treatment is targeted to women with a *T*-score of -2.5 SD at the femoral neck [15]. Since smoking carries a risk over and above that provided by BMD alone, intervention thresholds for BMD can be less stringent in smokers and still yield the same cost-effectiveness. This approach has been incorporated into health economic analyses [8, 50]. However, a large number of additional and stronger independent risk factors for fracture have been identified. These include a history of fracture, corticosteroid exposure, a family history of fracture, secondary osteoporosis, and possibly the biochemical indices of bone turnover [15, 51, 52, 53, 54]. Before these risk factors can be readily used for assessing fracture risk in the general population, their interrelationships will need to be determined.

We conclude that a history of smoking results in a substantial risk for future fractures and that this risk is largely independent of BMD. The fact that this association holds up on an international scale provides a rationale for using this risk factor in case-finding strategies. Moreover, identified patients can be targeted for treatment at lower BMD thresholds than are non-smoking individuals of the same age who have osteoporosis.

Acknowledgements We are grateful to the National Osteoporosis Foundation, the International Society for Clinical Densitometry and the European Union (FP3/5) for supporting this study. We also thank the Alliance for Better Bone Health, Hologic, IGEA, Lilly, GE Lunar, Novartis, Pfizer Roche and Wyeth for their unrestricted support. Personal potential conflicts of interest are acknowledged (J.A.K., O.J.), but in opposite directions.

References

- Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren P, Helfand M (2002) Osteoporosis in postmenopausal women: diagnosis and monitoring. In: Oregon Health and Science University Evidence-Based Practice Center (eds) Evidence report/technology assessment No. 28. Agency for Healthcare Research and Quality, Rockville, MD
- Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture; recognition of a major effect. *Br Med J* 315:841-846
- Huopio J, Kroger H, Honkanen R, Saarikoski S, Alhava E (2000) Risk factors for perimenopausal fractures: a prospective study. *Osteoporos Int* 11:219-227
- Bohannon AD, Hanlon JT, Landerman R, Gold DT (1999) Association of race and other potential risk factors with non-vertebral fractures in community-dwelling elderly women. *Am J Epidemiol* 149:1002-1009
- Mallmin H, Ljunghall S, Persson I, Bergstrom R (1994) Risk factors for fractures of the distal forearm: a population-based case-control study. *Osteoporos Int* 4:298-304
- Kelsey JL, Browner WS, Seeley DG, Nevitt MC, Cummings SR (1992) Risk factors for fracture of the distal forearm and proximal humerus. *Am J Epidemiol* 135:477-489
- Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. *New Engl J Med* 332:767-773
- National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. *Osteoporos Int [Suppl 4]* 8:1-88
- National Osteoporosis Foundation (1998) Physicians guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC, pp 1-38
- Brown J, Josse RG for the Scientific Advisory Council of the Osteoporosis Society of Canada (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. *Canad Med Assoc J [Suppl 10]* 167:S1-S34
- Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D on behalf of the EFFE (1997) Guidelines for the diagnosis and management of osteoporosis. *Osteoporos Int* 7:390-406
- Royal College of Physicians (1999) Osteoporosis: clinical guidelines for prevention and treatment. Royal College of Physicians, London
- Royal College of Physicians (2000) Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. Royal College of Physicians, London
- Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Melton J, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A (2002) A new approach to the development of assessment guidelines for osteoporosis. *Osteoporos Int* 13:527-536
- Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. *Lancet* 359:1929-1936
- Kreiger N, Tenenhouse A, Joseph L et al (1999) The Canadian Multicenter Osteoporosis Study (CaMos): background, rationale, methods. *Can J Aging* 18:376-387
- Jones G, Nguyen TV, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA (1994) Symptomatic fracture incidence in elderly men and women. The Dubbo Osteoporosis Epidemiology Study (DOES). *Osteoporos Int* 4:277-282
- Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN (1996) Risk factors for osteoporotic fractures in elderly men. *Am J Epidemiol* 144:255-263
- O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: European vertebral osteoporosis study. *J Bone Miner Res* 11: 1010-1017
- Felsenberg D, Silman AJ, Lunt M, Ambrecht G, Ismail AA, Finn JD, Cockerill WC, Banzer D, Benevolenskaya LI, Bhalla A, Bruges Armas J, Cannata JB, Cooper C, Dequeker J, Eastell R, Ershova O, Felsch B, Gowin W, Havelka S, Hoszowski K, Jajic I, Janot J, Johnell O, Kanis JA, Kragl G, Lopez Vaz A, Lorenc R, Lyritis G, Masaryk P, Matthis C, Miazgowski T, Parisi G, Pols HAP, Poor G, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, Reeve J, O'Neill TW (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). *J Bone Miner Res* 17:716-724
- Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, Banzer D, Benevolenskaya LI, Bhalla A, Bruges Armas J, Cannata JB, Cooper C, Delmas PD, Dequeker J, Dilsen G, Falch JA, Felsch B, Felsenberg D, Finn JD, Gennari C, Hoszowski K, Jajic I, Janott J, Johnell O, Kanis JA, Kragl G, Lopez Vaz A, Lorenc R, Lyritis G, Marchand F, Masaryk P,

- Matthis C, Miazgowski T, Naves-Diaz M, Pols HAP, Poor G, Rapado A, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, O'Neill TW (2002) Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). *Osteoporos Int* 13:565-571
22. Svanborg A (1977) 70-year-old people in Gothenburg. A population study in an industrialised Swedish city II. Journal Presentation of Social and Medical Conditions. *Acta Med Scand [Suppl]* 611:5
23. Johansson C, Black D, Johnell O, Oden A, Mellstrom D (1998) Bone mineral density is a predictor of survival. *Calcif Tissue Int* 63:190-196
24. Stenstrom M, Olsson JO, Mellstrom D (2000) Thyroid hormone replacement is not related to increased risk of osteoporosis. *Osteoporos Int [Suppl 2]* 11:S144.
25. Fujiwara S, Kasagi F, Yamada M, Kodama K (1997) Risk factors for hip fracture in Japanese cohort. *J Bone Miner Res* 12:998-1004
26. Fujiwara S, Fumiyoshi K, Masunari N, Naito K, Suzuki G, Fukunage M (2003) Fracture prediction from bone mineral density in Japanese men and women. *J Bone Miner Res* 18:1547-1553
27. Honkanen R, Kroger H, Tuppurainen M, Alhava E, Saarikoski S (1995) Fractures and low axial bone density in perimenopausal women. *J Clin Epidemiol* 48:881-888
28. Melton LJ 3rd, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL (2003) Relative contributions of bone density, bone turnover and clinical risk factors to long-term fracture prediction. *J Bone Miner Res* 18:312-318
29. Melton LJ 3rd, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL (1998) Bone density and fracture risk in men. *J Bone Miner Res* 13:1915-1923
30. Hofman A, Grobbee DE, De Jong PT, van den Ouweland FA (1991) Determinants of disease and disability in the elderly: the Rotterdam study. *Eur J Epidemiol* 7:403-422
31. De Laet CE, Van Hout BA, Burger H, Hofman A, Weel AE, Pols HAP (1998) Hip fracture prediction in elderly men and women: validation of the Rotterdam study. *J Bone Miner Res* 13:1587-1593
32. Johansson H, Oden A, Johnell O, Jonsson B, De Laet C, Oglesby A, McCloskey EV, Kayan J, Jalava T, Kanis JA (2003) Optimisation of BMD measurements to identify high-risk groups for treatment—a test analysis. *J Bone Miner Res* (in press)
33. Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. *Osteoporos Int* 12:417-427
34. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *Br Med J* 327:557-560
35. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *Lancet* 312:1254-1259
36. Cornuz J, Feskanich D, Willett WC et al (1999) Smoking, smoking cessation and risk of hip fracture in women. *Am J Med* 106:311-314
37. Sowers MR, Clark MK, Hollis B, Wallace RB, Jannausch M (1992) Radial bone mineral density in pre- and perimenopausal women: a prospective study of rates and risk factors for loss. *J Bone Miner Res* 7:647-657
38. Hannan MT, Felson DT, Dawson Hughes B, Tucker KL, Cupples LA, Wilson PWF, Keil DP (2000) Risk factors for longitudinal bone loss in elderly men and women. The Framingham Osteoporosis Study. *J Bone Miner Res* 15:710-720
39. Burger H, De Laet C, Van Daele P, Weel A, Witteman J, Hofman A, Pols H (1998) Risk factors of increased bone loss in an elderly population. The Rotterdam Study. *Am J Epidemiol* 147:871-879
40. Hermann AP, Brot C, Gram J, Kolthoff N, Mosekilde L (2000) Premenopausal smoking and bone density in 2,015 perimenopausal women. *J Bone Miner Res* 15:780-787
41. McKinlay SM, Bifano NL, McKinley JB (1985) Smoking and age at menopause in women. *Ann Intern Med* 103:350-356
42. Seeman E (1996) The effects of tobacco and alcohol use on bone. In: Marcus R, Feldman D, Kelsey J (eds) *Osteoporosis 1996*. Academic, San Diego, pp 577-597
43. Kiel DP, Baron JA, Anderson JJ, Hannan MT, Felson DT (1992) Smoking eliminates the potential effects of oral estrogens on the risk for hip fractures among women. *Ann Intern Med* 116:716-721
44. Hoidrup S, Gronbaek M, Pedersen AT, Lauritzen JB, Gottschau A, Schroll M (1999) Hormone replacement therapy and hip fracture risk: effects of modifications by tobacco smoking, alcohol intake, physical activity and body mass index. *Am J Epidemiol* 150:1085-1093
45. Johnell O, Gullberg B, Kanis JA, Allander E, Elffors L, Dequeker J, Dilsen G, Gennari C, Lopez Vaz A, Lyritis G, Mazzuoli G, Miravet L, Passeri M, Perez Cano R, Rapado A, Ribot C (1995) Risk factors for hip fracture in European women: the MEDOS study. *J Bone Miner Res* 10:1802-1815
46. Gunnes M, Mellstrom D, Johnell O (1998) How well can a previous fracture indicate a new fracture? A questionnaire study of 29,802 postmenopausal women. *Acta Orthop Scand* 69:508-512
47. Ensrud KE, Nevitt MC, Yunis C, Cauley JA, Seeley DG, Fox KM et al (1994) Correlates of impaired function in older women. *J Am Geriatr Soc* 42:481-489
48. Nelson HD, Nevitt ME, Scott JC, Stone KL, Cummings SR (1994) Smoking, alcohol and neuromuscular and physical function of older women. *JAMA* 272:1825-1831
49. Svendsen OL, Hassager C, Skodt T, Christiansen C (1995) Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine, hip and forearm: a human cadaveric study. *J Bone Miner Res* 10:868-873
50. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B (2001) Intervention thresholds for osteoporosis. *Bone* 31:26-31
51. Van Staa TP, Leufkens HGM, Cooper C (2002) Does a fracture at one site predict later fractures at other sites? A British cohort study. *Osteoporos Int* 13:624-629
52. Klotzbeucher CM, Ross PD, Landsman PB, Abbot TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res* 15:721-739.
53. Guidelines Writing Group (2002) Glucocorticoid-induced osteoporosis. Guidelines for prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians, London
54. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. *Osteoporos Int [Suppl 6]* 11:S2-S17

Saeko Fujiwara

Epidemiology of osteoporosis in Japan

Key words Epidemiology · Osteoporosis · Prevalence · Incidence · Spine fracture

Introduction

Osteoporosis is a common disease among postmenopausal women and the elderly, leading to an increased susceptibility to bone fracture. Spine fracture or hip fracture cause profound physical impairment and a reduction in quality of life in the elderly. In Japan, the average life expectancy is 84 years for women and 77 years for men, one of the longest in the world. More than 90% of women live to be 65, and about 70% are alive at the age of 80. With the lengthening of the life span, fractures related to osteoporosis become a major health problem and an enormous economic burden in Japan and Asian countries as well as in other developed countries. Spine fractures are the most common form of osteoporotic fractures, but few epidemiological studies of spine fracture are available in Japan or in other Asian countries. Results from such studies are discussed here.

Spine fracture prevalence

The prevalence of spine fracture varies according to the population studied and the diagnostic criteria used. Some reports exist on the prevalence of spine fracture in Japan. Because different diagnostic criteria were used in each cohort, however, we cannot strictly compare the prevalence among the three cohorts. The three prevalence studies [1–3] demonstrated that the prevalence of spine fracture ranged from 8% to 13% and from 30% to 40% in women in their sixties and seventies, respectively (Fig. 1).

S. Fujiwara (✉)

Department of Clinical Studies, Radiation Effects Research Foundation (RERF), 5-2 Hijiyama Park, Minami-ku, Hiroshima 732-0815, Japan
Tel. +81-82-261-3131; Fax +81-82-263-7279
e-mail: fujiwara@rerf.or.jp

In Asian countries, the prevalence among Japanese in Hiroshima was compared with that among Japanese-Americans in Hawaii and Caucasian Americans in Minnesota (United States) using the same diagnostic criteria [1]. In the criteria used, fractures were defined as vertebral height more than 3 standard deviations (SD) below the vertebra-specific mean. Compared to Japanese-Americans in Hawaii, the prevalence of spine fracture is greatest among Japanese in Hiroshima; odds ratios were 1.8 for Japanese women and 1.5 for American Caucasians (Fig. 2). A study in Hong Kong showed that the prevalence of spine fracture was 30% [4] in Chinese women aged 70–79, compared with 26% in American Caucasians, when a cutoff of 3 SD below the mean for vertebral height ratio was used. In Chinese people in Taiwan, the overall adjusted prevalence rate of spine fracture for women older than 65 was 20% and that for men 12.5% [5]. From these three studies, we may summarize that the prevalence of spine fracture in Asians is higher than that in Caucasians. However, a study in Beijing [6] demonstrated that the age-standardized prevalence of spine fracture was 5.5% lower among Chinese than that found using similar methods among women in Rochester, MN (USA). Further study is needed to determine if regional differences exist in the prevalence of spine fracture among Asian countries, or between Asians and Caucasians in the United States and Europe, using standardized diagnostic criteria.

Incidence of spine fracture

To our knowledge, there are only two reports determining the incidence of spine fracture among Japanese, but no reports about other Asian countries. Both reports in Japan are based on data obtained from the Adult Health Study (AHS) [7,8]. The AHS was established in 1950 to observe the late effects of radiation exposure among atomic bomb survivors in Hiroshima and Nagasaki. The original AHS cohort consisted of about 20000 atomic bomb survivors selected from residents in Hiroshima and Nagasaki using




Fig. 1. Comparison of prevalence of spine fracture among three regions in Japan




Fig. 2. International comparison of prevalence of spine fracture in women. SOF, Study of Osteoporotic Fractures

the 1950 national census. Since 1958, the AHS subjects have been followed through biennial health examinations including physical examination, measurements of height and weight, chest X-rays, and others. In a recent report [8], incidence of spine fracture was determined among about 2300 participants in the AHS during 1994 and 1996. Spine fracture was assessed using semiquantitative methods in which a new radiographic spine fracture was defined as a decrease of at least 20% in height of any vertebral body from initial reading to the end of the study.

The incidence of spine fracture increased exponentially with age among men and women. The age-specific incidence was twice as high in women as in men (Fig. 3). The incidence of spine fracture in the AHS cohort was compared with Caucasians in two European cohorts [9,10] (Fig. 3). Although we cannot compare these results strictly because of the use of different criteria for defining spine fractures, it seems that the incidence was about twofold higher in Hiroshima than in the Rotterdam and the European Prospective Osteoporosis Study (EPOS) cohorts.

Predictors for future fractures

Compared with Caucasians in the United States and Europe, bone mineral density (BMD) among Japanese is




Fig. 3. Comparison of incidence of spine fracture among Hiroshima cohort and cohorts in Europe. EPOS, European Prospective Osteoporosis Study

lower, the prevalence of spine fracture is higher, and the incidence of hip fracture is lower. It is well recognized that BMD could predict future fracture. In the United States and Europe, a number of prospective studies have assessed the value of BMD as a predictor of future fracture. However, there is one report [8] based on a longitudinal study on BMD and subsequent fracture risk in Japan and in other Asian countries.

The relationship between baseline BMD and future fracture risk was determined among about 2400 men and women who participated in the AHS from 1994 to 1995. The mean ages in the 1994–1995 examination of the subjects ± 1 SD were 62.9 ± 9.8 years for men and 65.4 ± 9.8 years for women. BMD at the spine (L2–L4) and proximal femur was measured at each biennial health examination using dual X-ray absorptiometry (DXA; QDR-2000; Hologic, Waltham, MA, USA). During the follow-up period, 27 men and 149 women developed a new spine fracture and 21 women but no men developed a new hip fracture. Follow-up averaged 4 years after baseline measurements of BMD.

Multivariate analyses showed that age, baseline BMD at the spine and hip, and prior spine fracture independently predicted future spine fracture in both men and women and hip fracture in women. However, weight, height, body mass index (BMI), and age at menopause did not predict spine fracture after adjusting for age, BMD, and prior spine fracture.

After adjusting for prior spine fracture, both baseline spine and femoral neck BMD predicted spine and hip fracture risk, and the relative risk declined with age. This finding suggests that the contribution of fracture risk factors such as falls and neuromuscular impairment other than BMD may be greater to develop hip or spine fracture among the eldest population. The meta-analysis [11] showed that most measurement sites had virtually the same predictive ability for a decrease of 1 SD in BMD, and each standard deviation reduction in BMD at the spine or hip increased the age-adjusted risk of fracture by a factor of about 2. However, femoral neck BMD was better for

Table 1. Relative risk for fracture per 1 SD decrease in bone mineral density (BMD): Japanese vs. Caucasian women

Population	Site of BMD	Fracture site	
		Spine	Hip
Japanese [8]	Spine	1.5 (1.3–1.9)	1.4 (1.0–2.5)
Meta-analysis [11]		1.9 (1.8–2.0)	1.5 (1.3–1.7)
Japanese [8]	Femoral neck	1.8 (1.4–2.3)	2.9 (1.3–4.4)
Meta-analysis [11]		1.9 (1.8–2.1)	2.4 (2.2–2.6)

predicting hip fracture, with relative risk of 2.6. Comparing the relative risks between Japanese and Caucasian populations, the relative risk for spine or hip fracture per decrease in BMD is similar in Japanese to that in other populations including Caucasians in the United States and Europe (Table 1), even if BMD at the same age differed between these populations.

After adjusting for age and baseline spine BMD, prior spine fracture was associated with about a fourfold increase in future spine fracture risk among men and a threefold increase among women. Numerous studies and meta-analysis [12,13] using mainly Caucasian populations have reported that prior fracture is an independent risk factor for future fracture among men and women, with a relative risk of about 2. Prior fracture is an important predictor for future fracture among Japanese as well as among Caucasian populations.

In summary, age, BMD, and prior spine fracture are important predictors of future fracture among Japanese. Predictive abilities of BMD and prior fracture for future fracture are similar in men and women, and similar in Japanese and Caucasians.

Conclusions

Epidemiological studies in Japan and in other Asian countries have demonstrated that prevalence or incidence of spine fracture differed among regions and countries, and most of the results showed that the prevalence of spine fracture was higher among Asians compared with Caucasians in the United States and Europe. The prospective study in Japan demonstrated that BMD and prior fracture could predict future fracture in Japanese as well as BMD did in the other cohorts in the United States and Europe, with similar predictive ability.

In Asian countries, several cross-sectional epidemiological studies have been conducted, but few prospective studies. More prospective studies are needed in Asian countries to clarify the incidence and relationship between risk factors, including BMD and future fracture risk.

References

- Ross PD, Fujiwara S, Huang C, Davis JW, Epstein RS, Wasnich RD, Kodama K, Melton LJ III (1995) Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. *Int J Epidemiol* 24:1171–1177
- Yoshimura N, Kinoshita H, Danjyo S, Yamada H, Tamaki T, Morioka S, Kasamatsu T, Hashimoto T, Inoue T (1995) Prevalence of vertebral fractures in a rural Japanese population. *J Epidemiol* 5:171–175
- Kitazawa A, Kushida K, Yamazaki K, Inoue T (2001) Prevalence of vertebral fracture in a population-based sample in Japan. *J Bone Miner Metab* 19:115–118
- Lau EMC, Chan HHL, Woo J, Lin F, Black D, Nevitt M, Leung PC (1996) Normal ranges for vertebral height ratios and prevalence of vertebral fracture in Hong Kong Chinese: a comparison with American Caucasians. *J Bone Miner Res* 11:1364–1368
- Tsai K, Twu S, Chieng P, Yang R, Lee T (1996) Prevalence of vertebral fracture in Chinese men and women in urban Taiwanese communities. *Calcif Tissue Int* 59:249–253
- Ling X, Cummings SR, Mingwei Q, Xihe Z, Xioashu C, Nevitt M, Stone K (2000) Vertebral fractures in Beijing, China: the Beijing Osteoporosis Project. *J Bone Miner Res* 15:2019–2025
- Fujiwara S, Mizuno S, Ochi Y, Sasaki H, Kodama K, Russell WJ, Hosoda Y (1991) The incidence of thoracic vertebral fractures in a Japanese population, Hiroshima and Nagasaki, 1958–86. *J Clin Epidemiol* 44:1007–1014
- Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. *J Bone Miner Res* 18:1547–1553
- The European Prospective Osteoporosis Study (EPOS) Group (2002) Incidence of vertebral fracture in Europe. Results from the European Prospective Osteoporosis Study (EPOS). *J Bone Miner Res* 17:716–724
- Van Der Klift M, De Laet CEDH, McCloskey EV, Hofman A, Pols HA (2002) The incidence of vertebral fracture in men and women: the Rotterdam Study. *J Bone Miner Res* 17:1051–1056
- Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 312:1254–1259
- Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res* 15:721–739
- Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eismans JA, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. *Bone* 35:375–382

SPECIAL REPORT

Hajime Nawata · Satoshi Soen · Ryoichi Takayanagi
Ikuko Tanaka · Kunio Takaoka · Masao Fukunaga
Toshio Matsumoto · Yasuo Suzuki · Hiroyuki Tanaka
Saeko Fujiwara · Takami Miki · Akira Sagawa
Yoshiki Nishizawa · Yoshiki Seino
The Subcommittee to Study Diagnostic Criteria for
Glucocorticoid-Induced Osteoporosis

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004)

Received: November 22, 2004 / Accepted: December 17, 2004

Key words Steroid (glucocorticoid) · Osteoporosis · Guideline

Introduction

Osteoporosis is the most frequent adverse effect of glucocorticoids. Management guidelines were developed [1] in the United States in 1996 when the seriousness of glucocorticoid-induced osteoporosis as a complication of glucocorticoid therapy was recognized, and they have since been revised [2–6]. In Japan, the Japanese Society for Bone and Mineral Research established a study group on

osteoporosis diagnostic criteria in 1999 and then the Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis in 2001 to examine diagnostic criteria for glucocorticoid-induced osteoporosis, and the present guidelines were developed for clinical practice (Fig. 1).

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis

Drafting policy

The Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis was initially organized to determine diagnostic criteria. However, guidelines on glucocorticoid-induced osteoporosis in various countries

H. Nawata (✉)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Tel. +81-92-642-5275; Fax +81-92-642-5297
e-mail: nawata@intmed3.med.kyushu-u.ac.jp

S. Soen

Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine, Ikoma, Japan

R. Takayanagi

Department of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

I. Tanaka

Department of Laboratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan

K. Takaoka

Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

M. Fukunaga

Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Japan

T. Matsumoto

Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan

Y. Suzuki

Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan

H. Tanaka

Department of Pediatrics Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan

S. Fujiwara

Department of Clinical Studies, Radiation Effects Research Foundation, Chiba, Japan

T. Miki

Geriatric Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan

A. Sagawa

Center for Rheumatic Diseases, Sapporo Yamanoue Hospital, Sapporo, Japan


Y. Nishizawa

Department of Metabolism, Endocrinology & Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan

Y. Seino

Japanese Society for Bone and Mineral Research, Osaka, Kosei Nenkin Hospital, Osaka, Japan

Fig. 1. Guidelines on the management and treatment of corticosteroid-induced osteoporosis (2004 edition)^a



• General guidance

Lifestyle guidance, nutritional guidance, and exercise therapy are based on those for primary osteoporosis

• Follow-up observation

Bone mineral density measurements and thoracic and lumbar vertebra X-rays are performed on a regular basis (every 6 months or 1 year)

• Drug treatment

1. Bisphosphonates are first-line drugs
2. Active vitamin D₃ and vitamin K₂ are second-line drugs

YAM, young adult mean (20–44 years old), BMD, bone mineral density

^aThese Guidelines cover patients 18 years of age and older

^bDefinition of fragility fractures is the same as that for primary osteoporosis

^cBone mineral density (BMD) measurements are based on those for primary osteoporosis (2000 revised edition)

^dMean daily dose

^ePatients administered 10 mg or more per day are at risk of fractures even when bone mineral density is high (out-off value, %YAM80)

^fRisk of fractures is higher in the elderly

are guidelines for primary and secondary prevention and do not specify diagnostic criteria. The subcommittee discussed this point, and a draft of management and therapeutic guidelines in Japan based on evidence available at present was prepared.

Patients studied by the Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis

The survey items were sex, age, height, body weight, underlying disease, bone mineral density (type of instrument used, region, measured value), glucocorticoid treatment history (dose, mean dose for 6 months until measurement of bone mineral density, maximum dose throughout administration period, total administration period, total dose, pulse therapy within 1 year, use of glucocorticoids for inhalation), osteoporosis treatment history, and fracture history. The facilities connected with the Subcommittee, that is, Osaka

City University, Kawasaki Medicine University, Kyushu University, Kyushu University Hospital at Beppu, Kinki University, Sapporo Yamanoue Hospital, Research Institute and Practice for Involuntional Diseases, Tokyo Metropolitan Tama Geriatric Hospital, Tokyo Metropolitan Geriatric Medical Center, Hamamatsu University School of Medicine, Fujita Health University, and Radiation Effects Research Foundation, were requested to conduct the survey. As a result, a total of 692 patients were recruited up to 2002 in addition to the 299 patients recruited in 1999 and 2000, including 627 women and 65 men. The most common underlying disease was rheumatoid arthritis (RA) in 319 patients, and 373 patients had diseases other than RA; these included 162 cases of systemic lupus erythematosus (SLE), 27 of progressive systemic sclerosis (PSS), 26 with mixed connective tissue disease (MCTD), 20 with polymyositis/dermatomyositis (PM/DM), 16 with polymyalgia rheumatica (PMR), 12 with nephrosis, 10 with asthma, 10 with idiopathic thrombocytopenic purpura

(ITP), and 90 with other diseases. The results of an analysis of a 2-year follow-up survey on 220 patients administered glucocorticoids by Tanaka and Oshima [7] were added to these analytical results, and work on establishment of the guidelines proceeded.

Evidence for drafting the guidelines

Subjects

These guidelines cover men and women 18 years of age or older. Growth disorders caused by glucocorticoids are a serious problem in children, but at present no evidence that can be used has been reported in Japan or overseas, and children were excluded. Because of the same lack of evidence concerning glucocorticoids injected intravenously, only patients using oral glucocorticoids for which evidence is available in Japan and overseas were subjects. There is no evidence concerning the administration period in Japan. The most recent guidelines of the United States, UK, and Canada cover treatment with administration for 3 months or longer [3–6]. In a meta-analysis of the risk of bone fractures after starting treatment with oral glucocorticoids overseas, it was reported that the incidence of new vertebral bone fractures reaches a maximum at 3–6 months after administration and forms a plateau thereafter [8], suggesting that treatment simultaneously with or in the very early stage of glucocorticoid administration is important. Therefore, the subjects were patients with planned administration for 3 months or longer (see Fig. 1).

Prior fragility fractures

The results of an analysis in a 2-year longitudinal study by Tanaka and Oshima showed that the risk of new bone fractures in patients with prior fragility fractures showed the highest value compared with other fractures at an odds ratio of 7.92 [7]. Among the patients collected by the Subcommittee to Study Diagnostic Criteria, the 154 cases (103 cases of RA, 51 cases of collagen disease) that could be analyzed longitudinally for 2 years had a high odds ratio of 5.22. Therefore, the first evaluation criterion for starting treatment was patients with prior fragility fractures and patients with new bone fractures during treatment. The definition of a fragility fracture is the same as that for primary osteoporosis [9].

Bone mineral density

Table 1 shows the cut-off values of bone mineral density (BMD), which can efficiently separate fracture and non-fracture cases, estimated from the receiver-operating characteristic (ROC) curve based on an analysis of cases collected by the Subcommittee to Study Diagnostic Criteria. The cut-off value for all patients was 0.776 g/cm². When the patients were divided into those with RA, the most common underlying disease, and those with diseases other than RA, the cut-off values were 0.744 g/cm² and 0.820 g/cm², respectively. In cases with SLE, the most common underlying disease other than RA, the cut-off value was 0.841 g/cm². Judging from these results, it appeared necessary to set different cut-off values for RA and for other underlying diseases. Table 2 shows the results of an investigation of this point with respect to age. In Table 2, all patients were grouped by age from those less than 40 to those 70 years of age and older. The cut-off values of bone mineral density in fracture and nonfracture cases were obtained by age and expressed as percent (%) young adult mean (YAM). When the level of differences in cut-off values (%YAM) was examined for age differences of 10 years, the values were 6.5% for patients in their forties and in their fifties and 7.1% for patients in their fifties and in their sixties. The mean age of RA patients was 60.4 years and that for diseases other than RA 48.8 years, an age difference of 11.6 years. The cut-off values were 73.6% for RA and 81.1% for diseases other than RA, a difference of 7.5%; i.e., this difference was almost the same as that for age, and the difference in cut-off values of RA and diseases other than RA is not considered as a difference caused by differences in disease but a difference due to age.

Table 1. Cut-off values of bone mineral density (BMD) to efficiently separate fracture and nonfracture cases

	BMD (g/cm ²)	T score	% YAM	
Primary osteoporosis	0.708	-2.60	70%	
Osteopenia	0.809	-1.70	80%	
Glucocorticoid-treated patients	All patients	0.776	-1.97	76.8%
	RA	0.744	-2.24	73.6%
	Non-RA	0.820	-1.60	81.1%
	SLE	0.841	-1.43	83.2%

YAM, young adult mean; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus

Table 2. Cut-off values of bone mineral density by age and underlying disease of patients administered glucocorticoid

Age (all patients)	%YAM	Mean age (years)	Underlying disease
Less than 40 years old	86.9		
Forties	85.9	48.8	Non-RA
Fifties	79.4		
Sixties	72.3		
Seventies and older	69.3	60.4	RA

6.5% difference between Forties and Fifties; 7.1% difference between Fifties and Sixties; 7.5% difference between Non-RA and RA.

Table 3. Cut-off values of bone mineral density by dose of glucocorticoids

	Daily dose (prednisolone equivalent) (mg)	%YAM (T score)
All patients	≧5	77.7 (-1.90)
	≧7.5	80.3 (-1.67)
	≧10	82.1 (-1.52)
RA	≧7.5	75.1 (-2.12)
Non-RA	≧5	81.8 (-1.55)
	≧7.5	82.6 (-1.48)

Table 3 shows the relationship between glucocorticoid dose and the cut-off values. In all patients, the cut-off value (%YAM) in the group with a prednisolone equivalent dose of 5 mg/day or higher was 77.7%, that in the group with a dose of 7.5 mg/day or higher was 80.3%, and that in the group with a dose of 10 mg/day or higher was 82.1%. These results showed that as the daily dose increased, fractures occurred at higher bone mineral densities. For RA, the cut-off value was 75.1% in the group with a prednisolone equivalent dose of 7.5 mg/day or higher, and for diseases other than RA, it was 81.8% in the group with a dose of 5 mg/day or higher and 82.6% in the group with a dose of 7.5 mg/day or higher. The results of a cross-sectional analysis of all patients collected by the Subcommittee to Study Diagnostic Criteria showed a cut-off value of %YAM 77%, and the cut-off value in the group with a prednisolone equivalent dose of 5 mg/day or higher, at which it was reported based on a meta-analysis that the bone mineral density rapidly decreased and bone fractures increased, was 78%. It was clear that it is not necessary to consider differences in cut-off values due to differences in underlying diseases. In the longitudinal analysis by Tanaka and Oshima, the cut-off value in the group with a prednisolone equivalent dose of 5 mg/day or higher was %YAM 80% [7]. Based on these results, bone mineral density of less than %YAM 80% was taken as the second evaluation criterion for starting treatment.

Dose of glucocorticoids

The number of patients collected by the Subcommittee was not enough to clarify the relationship between the fracture risk and the total glucocorticoid dose, and the analysis could not be performed. Almost no difference was found in the relationship between the fracture risk and the administration period, but this was because of insufficient data on individual patients, and the relationship will have to be clarified in the future. Sufficient evidence on the relationship between the glucocorticoid dose and fracture risk rate or its cut-off value of bone mineral density has still not been obtained in Japan, and overseas reports had to be used for reference. The results of an overseas meta-analysis showed a reverse correlation between the bone mineral density of the lumbar vertebra and the total dose of glucocorticoid (daily dose × period), and the risk of a spinal fracture even at a daily dose of less than 2.5 mg of prednisolone equivalent

was more than 1.0, i.e., 1.55. The fracture rate increased dose dependently and was 5.18 at 7.5 mg or higher doses [8]. It has been reported that a dose of 5 mg or higher is the threshold value for increased fracture risk. Therefore, the third evaluation criterion for the start of treatment was proposed as a dose of 5 mg/day or higher (mean daily dose) as prednisolone equivalent (see Fig. 1). However, in a longitudinal study, the cut-off value of bone mineral density was %YAM 90% in the group administered a 10 mg/day or higher dose of prednisolone equivalent, and even at a %YAM close to 100%, the risk rate of fractures was clearly higher in the patients given glucocorticoid than in patients not administered glucocorticoids [7].

Old age

In the study by Tanaka and Oshima [7], the incidence of bone fractures increased significantly with increase in age, and age was identified as a risk factor of new spinal fractures in patients administered glucocorticoids; however, a cut-off value of age to clearly separate fracture and nonfracture cases could not be determined.

Treatment of glucocorticoid-induced osteoporosis

General guidance. In the same way as with primary osteoporosis, it is necessary to provide guidance on improvements in lifestyle and on nutrition, as well as exercise therapy. This guidance is based on that given for primary osteoporosis [10].

Follow-up observation. The risk of bone fractures is higher in patients administered glucocorticoid than in those who were not treated with glucocorticoid. Therefore, in patients evaluated as the follow-up observation group based on the present guidelines, it is essential to conduct follow-up observation by measuring bone mineral density and taking X-rays of the thoracic and lumbar vertebra on a regular basis.

Drug treatment. In prospective randomized control trials (RCT) overseas [11–15] and in Japan [16,17], evidence that the bisphosphonate products etidronate, alendronate, and risedronate significantly prevent bone fractures caused by glucocorticoid-induced osteoporosis has been reported. Therefore, these drugs have been recommended as first-line drugs at present. Active vitamin D₃ has been reported to have fracture-preventing effects, although these are inferior to those of the bisphosphonates [18], and vitamin K₂ has also been found to have fracture-preventing effects from a longitudinal study in Japan [7]. These two vitamins have been recommended as second-line drugs. Although the parameter was bone mineral density, it was reported based on a meta-analysis that vitamin D and bisphosphonates administered concomitantly are more effective than bisphosphonates alone in the treatment of glucocorticoid-induced osteoporosis [19]. Concomitant administration of active vitamin D₃ and bisphosphonates should be considered in patients with serious or high-risk osteoporosis. When bisphosphonates are difficult to administer to postmeno-

pausal women because of problems such as side effects, selection of raloxifene, a selective estrogen receptor modulator (SERM) [4,20,21] may be considered; however, therapeutic evidence of SERM for glucocorticoid-induced osteoporosis is still insufficient and further study will be necessary.

Conclusion

The 2004 edition of the guidelines on the management and treatment of glucocorticoid-induced osteoporosis has been developed based on the results of a longitudinal study by subcommittee members and the results of an analysis of patients collected by the Subcommittee to Study Diagnostic Criteria for Corticosteroid-Induced Osteoporosis, together with evidence obtained overseas and in Japan at present. It will be necessary to verify and revise the present guidelines based on newly collected evidence in the future.

References

- American College of Rheumatology Task Force on Osteoporosis Guidelines (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Rheum* 39:1791-1801
- Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ (1998) A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. *J Intern Med* 244:271-292
- Adachi JD, Olszynski WP, Hanley DA, Hodsmann AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS, Blocka KL, Pollock AP, Sibley J (2000) Management of corticosteroid-induced osteoporosis. *Semin Arthritis Rheum* 29:228-251
- American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Update. *Arthritis Rheum* 44:1496-1503
- Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. *Can Med Assoc J* 167:1S-34S
- Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. Royal College of Physicians, London
- Tanaka I, Oshima H (2003) A longitudinal study of diagnosis and treatment for glucocorticoid-induced osteoporosis. *Osteoporosis Jpn* 11:11-14
- Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporosis Int* 13:777-787
- Orimo H, Hayashi Y, Fukunaga H, et al (2001) Diagnostic criteria of primary osteoporosis (2000 revision). *Jpn J Bone Miner Res* 18:76-82
- Working Group on Preparation of Guidelines on Treatment of Osteoporosis (Drug Treatment) (representative, Orimo H) (2002) Guidelines on treatment of osteoporosis (drug treatment). 2002 revision. *Osteoporosis Jpn* 10:637-709
- Adachi JD, Bensen WG, Brown J, Hanley D, Hodsmann A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med* 337:382-387
- Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. *N Engl J Med* 339:292-299
- Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum* 42:2309-2318
- Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. *J Bone Miner Res* 15:1006-1013
- Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RE, et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. *Arthritis Rheum* 44:202-211
- Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M (2003) Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. *J Rheumatol* 30:2673-2679
- Nakayamada S, Okada Y, Saito K, Tanaka Y (2004) Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. *J Rheumatol* 31:163-166
- De Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D(3) analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. *Osteoporosis Int* 16:625-632
- Amin S, Lavalley MP, Simms RW, Felson DT (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. *J Bone Miner Res* 17:1512-1526
- Sambrook PN, Diamond T, Ferris L, Flatarone-Singh M, Flicker L, MacLennan A, Nowson C, O'Neill S, Greville H (2001) Corticosteroid-induced osteoporosis. Guidelines for treatment. *Aust Fam Physician* 30:793-796
- Sewell K, Schein JR (2001) Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects. *Semin Arthritis Rheum* 30:288-297